We narrowed to 461 results for: AAV9

#98929-AAV9

Ready-to-use AAV9 particles produced from pAAV.hSyn.iGluSnFr.WPRE.SV40 (#98929). In addition to the viral particles, you will also receive purified pAAV.hSyn.iGluSnFr.WPRE.SV40 plasmid DNA. Synapsin-driven, iGluSnFr glutamate sensor. These AAV preparations are suitable purity for injection into animals.

Loren Looger

Marvin et al Nat Methods. 2013 Feb;10(2):162-70. doi:

April 2, 2018

Academic Institutions and Nonprofits only

#140552-AAV9

Ready-to-use AAV9 particles produced from pAAV-hsyn-GRAB_5-HT1.0 (#140552). In addition to the viral particles, you will also receive purified pAAV-hsyn-GRAB_5-HT1.0 plasmid DNA. Synapsin-driven expression of GRAB_5-HT1.0 sensor. These AAV preparations are suitable purity for injection into animals.

Yulong Li

Wan et al Nat Neurosci. 2021 Apr 5. pii: 10.1038/s

Aug. 31, 2021

Academic Institutions and Nonprofits only

#100841-AAV9

Ready-to-use AAV9 particles produced from pAAV.Syn.GCaMP6m.WPRE.SV40 (#100841). In addition to the viral particles, you will also receive purified pAAV.Syn.GCaMP6m.WPRE.SV40 plasmid DNA. Syn-driven GCaMP6m calcium sensor. These AAV preparations are suitable purity for injection into animals.

Douglas Kim, GENIE Project

Chen et al Nature. 2013 Jul 18;499(7458):295-300. d

April 17, 2018

Academic Institutions and Nonprofits only

#22222-AAV9

Ready-to-use AAV9 particles produced from AAV-FLEX-Arch-GFP (#22222). In addition to the viral particles, you will also receive purified AAV-FLEX-Arch-GFP plasmid DNA. CAG-driven cre-dependent Arch-GFP expression for optogenetic neural inhibition. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Chow et al Nature. 2010 Jan 7. 463(7277):98-102.

Feb. 20, 2018

Academic Institutions and Nonprofits only

#55641-AAV9

Ready-to-use AAV9 particles produced from pAAV-Ef1a-fDIO EYFP (#55641). In addition to the viral particles, you will also receive purified pAAV-Ef1a-fDIO EYFP plasmid DNA. EF1a-driven, Flp-dependent expression of EYFP. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Fenno et al Nat Methods. 2014 Jul;11(7):763-72. doi:

Feb. 25, 2021

Academic Institutions and Nonprofits only

#35509-AAV9

Ready-to-use AAV9 particles produced from pAAV-Ef1a-DIO hChR2(E123T/T159C)-EYFP (#35509). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO hChR2(E123T/T159C)-EYFP plasmid DNA. EF1a-driven, Cre-dependent, humanized channelrhodopsin E123T/T159C mutant fused to EYFP for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Mattis et al Nat Methods. 2011 Dec 18;9(2):159-72. do

Feb. 21, 2018

Academic Institutions and Nonprofits only

#124603-AAV9

Ready-to-use AAV9 particles produced from pAAV-EF1a-DIO-ChrimsonR-mRuby2-KV2.1-WPRE-SV40 (#124603). In addition to the viral particles, you will also receive purified pAAV-EF1a-DIO-ChrimsonR-mRuby2-KV2.1-WPRE-SV40 plasmid DNA. EF1a-driven, Cre-dependent expression of ChrimsonR fused to mRuby2 fluorophore and targeted to neuronal soma for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Christopher Harvey

Chettih et al Nature. 2019 Mar 6. pii: 10.1038/s41586-

Sept. 26, 2019

Academic Institutions and Nonprofits only

#113050-AAV9

Ready-to-use AAV9 particles produced from pAAV-hSyn-GRAB_DA1h (#113050). In addition to the viral particles, you will also receive purified pAAV-hSyn-GRAB_DA1h plasmid DNA. Synapsin-driven expression of GRAB-DA1h dopamine sensor in neurons. These AAV preparations are suitable purity for injection into animals.

Yulong Li

Sun et al Cell. 2018 Jul 12;174(2):481-496.e19. do

Nov. 19, 2019

Academic Institutions and Nonprofits only

#83897-AAV9

Ready-to-use AAV9 particles produced from pAAV-hDlx-GqDREADD-dTomato-Fishell-4 (#83897). In addition to the viral particles, you will also receive purified pAAV-hDlx-GqDREADD-dTomato-Fishell-4 plasmid DNA. hDlx-driven expression of GqDREADD (hM3D) and nuclear localized dTomato (physically separate) for activation of interneurons. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Dimidschstein et al Nat Neurosci. 2016 Oct 31. doi: 10.1038/

Nov. 2, 2020

Academic Institutions and Nonprofits only

#140556-AAV9

Ready-to-use AAV9 particles produced from pAAV-hsyn-GRAB_rDA1m (#140556). In addition to the viral particles, you will also receive purified pAAV-hsyn-GRAB_rDA1m plasmid DNA. Synapsin-driven expression of red fluorescent medium affinity dopamine sensor GRAB_rDA1m. These AAV preparations are suitable purity for injection into animals.

Yulong Li

Sun et al Nat Methods. 2020 Nov;17(11):1156-1166.

Aug. 31, 2021

Academic Institutions and Nonprofits only

#154951-AAV9

Ready-to-use AAV9 particles produced from hSyn-DIO-somBiPOLES-mCerulean (#154951). In addition to the viral particles, you will also receive purified hSyn-DIO-somBiPOLES-mCerulean plasmid DNA. Synapsin-driven, Cre-dependent expression of soma-targeted BiPOLES for optogenetic inhibition (blue light) and activation (red light). These AAV preparations are suitable purity for injection into animals.

Simon Wiegert

Vierock et al Nat Commun. 2021 Jul 26;12(1):4527. doi:

Sept. 1, 2021

Academic Institutions and Nonprofits only

#83900-AAV9

Ready-to-use AAV9 particles produced from pAAV-mDlx-GFP-Fishell-1 (#83900). In addition to the viral particles, you will also receive purified pAAV-mDlx-GFP-Fishell-1 plasmid DNA. mDlx-driven expression of GFP in GABA-ergic interneurons. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Dimidschstein et al Nat Neurosci. 2016 Oct 31. doi: 10.1038/

Nov. 13, 2020

Academic Institutions and Nonprofits only

#162380-AAV9

Ready-to-use AAV9 particles produced from pGP-AAV-CAG-FLEX-jGCaMP8s-WPRE (#162380). In addition to the viral particles, you will also receive purified pGP-AAV-CAG-FLEX-jGCaMP8s-WPRE plasmid DNA. CAG-driven, Cre-dependent expression of calcium sensor GCaMP8s (more sensitive). These AAV preparations are suitable purity for injection into animals.

GENIE Project

Zhang et al Janelia Research Campus, Online Resource

June 22, 2021

Academic Institutions and Nonprofits only

#83899-AAV9

Ready-to-use AAV9 particles produced from pAAV-mDlx-GCaMP6f-Fishell-2 (#83899). In addition to the viral particles, you will also receive purified pAAV-mDlx-GCaMP6f-Fishell-2 plasmid DNA. mDlx-driven expression of GCaMP6f. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Dimidschstein et al Nat Neurosci. 2016 Oct 31. doi: 10.1038/

Nov. 13, 2020

Academic Institutions and Nonprofits only

#107712-AAV9

Ready-to-use AAV9 particles produced from pAAV-hSynapsin-FLEX-soCoChR-GFP (#107712). In addition to the viral particles, you will also receive purified pAAV-hSynapsin-FLEX-soCoChR-GFP plasmid DNA. Synapsin-driven, Cre-dependent somatic CoChR (soCoChR) fused to GFP for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Shemesh et al Nat Neurosci. 2017 Dec;20(12):1796-1806.

Sept. 7, 2018

Academic Institutions and Nonprofits only

#174007-AAV9

Ready-to-use AAV9 particles produced from pAAV-hSyn-DIO-jGCaMP8s-P2A-ChrimsonR-ST (#174007). In addition to the viral particles, you will also receive purified pAAV-hSyn-DIO-jGCaMP8s-P2A-ChrimsonR-ST plasmid DNA. Syn-driven, Cre-dependent expression of calcium sensor GCaMP8s and soma-targeted ChrimsonR. These AAV preparations are suitable purity for injection into animals.

Mark Histed

LaFosse et al eNeuro. 2023 Mar 29;10(3):ENEURO.0378-22

May 4, 2023

Academic Institutions and Nonprofits only